Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05732727
PHASE3

Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease

Sponsor: University Hospital, Tours

View on ClinicalTrials.gov

Summary

Chronic kidney disease (CKD) is a major public health issue worldwide. Hypertension is the first risk factor in patients with CKD for mortality, cardiovascular disease and end-stage renal disease. It's now well established that lowering blood pressure (BP) reduces renal and cardiovascular complications in this high-risk population. In the general population, in addition to lifestyle interventions, the strategy to initiate and escalate a BP-lowering drug treatment is well described. The drug therapies recommended to achieve optimal BP control in the general population are the following: blockers of the renin-angiotensin system (angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)), diuretics (thiazides and thiazide-like diuretics), and calcium channel blockers. For patients with CKD, the guidelines advise to start the BP-lowering agent with ACEi or ARB, but then, there is no strong evidence to support the preferential use of any particular agent in controlling BP and the results of clinical trials are discordant. In the NephroTest cohort, a French cohort of patients with CKD stage 1 to 5, among 2015 patients, 1782 had hypertension, only 54% had a diuretic and 44% had uncontrolled hypertension. In this cohort, extracellular fluid (ECF) overload was an independent determinant of hypertension, uncontrolled hypertension and apparent treatment resistant hypertension. In the same cohort, ECF overload was independently associated with end-stage kidney disease and death. Our hypothesis is that patients with CKD and uncontrolled hypertension are fluid overloaded and that the second line of treatment after an ACEi or an ARB should be a diuretic. We hypothesize that a specific algorithm to lower BP in patients with moderate to severe CKD based on diuretics will be more effective in term of cardiovascular event, mortality and evolution to end-stage kidney disease as compared to standard of care.

Official title: Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease: an Open Label, a Cluster Randomized Controlled, Phase 3 Trial

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

720

Start Date

2023-03-28

Completion Date

2029-03

Last Updated

2025-12-01

Healthy Volunteers

No

Interventions

DRUG

Antihypertensive algorithm

Antihypertensive algorithm based on diuretics agents

DRUG

Standard of care

standard of care management for antihypertensive therapy intensification

Locations (40)

Department of Nephrology, University Hospital of Angers

Angers, France

Department of Nephrology, University Hospital of Bordeaux

Bordeaux, France

AUB Santé foundation, Brest

Brest, France

Department of Nephrology, University Hospital of Brest

Brest, France

Department of Nephrology, Hospital of Chalon-sur-Saône

Chalon-sur-Saône, France

Department of Nephrology, Hospital of Chartres

Chartres, France

Department of Nephrology, University Hospital of Clermont-Ferrand

Clermont-Ferrand, France

Department of Nephrology, Hospital of Colmar

Colmar, France

Department of Nephrology, University Hospital of Grenoble

Grenoble, France

Department of Nephrology, Hospital of Haguenau

Haguenau, France

Department of Nephrology, Departemental Hospital of Vendée

La Roche-sur-Yon, France

ECHO Santé Association, Le Mans

Le Mans, France

Department of Nephrology, Hospital of Le Puy en Velay

Le Puy-en-Velay, France

Department of Nephrology, University Hospital of Lille

Lille, France

Department of Nephrology, University Hospital of Limoges

Limoges, France

AUB Santé foundation, Lorient

Lorient, France

Department of Nephrology, University Hospital of Lyon

Lyon, France

Department of Nephrology, University Hospital of Marseille

Marseille, France

Department of Nephrology, Regional Hospital of Metz

Metz, France

Department of Nephrology, Régional Hospital of Mulhouse

Mulhouse, France

Department of Nephrology, University Hospital of Nantes

Nantes, France

ECHO Santé Association, Nantes

Nantes, France

Department of Nephrology, University Hospital of Nîmes

Nîmes, France

Department of Nephrology, Hospital of Orléans

Orléans, France

Department of Nephrology, European Hospital Georges Pompidou, AP-HP

Paris, France

Department of Nephrology, Necker Hospital, AP-HP

Paris, France

Department of Nephrology, Bichat Hospital, AP-HP

Paris, France

Department of Nephrology, Tenon Hospital, AP-HP

Paris, France

Department of Nephrology, Hospital of Perpignan

Perpignan, France

Department of Nephrology, University Hospital of Reims

Reims, France

Department of Nephrology, University Hospital of Rennes

Rennes, France

Department of Nephrology, Hospital of Roubaix

Roubaix, France

Department of Nephrology, University Hospital of Rouen

Rouen, France

Department of Nephrology, University Hospital of Saint Etienne

Saint-Etienne, France

ECHO Santé Association, Saint Herblain

Saint-Herblain, France

Department of Nephrology, Hospital of Saint Malo

St-Malo, France

Department of Nephrology, Hospital of Strasbourg

Strasbourg, France

Department of Nephrology, University Hospital of Tours

Tours, France

Department of Nephrology, Hospital of Valenciennes

Valenciennes, France

Department of Nephrology, University Hospital of Nancy

Vandœuvre-lès-Nancy, France